NCT06467903

Brief Summary

A prospective, comparative multicenter evaluation conducted to capture patients with diabetic retinopathy in general practitioners, using AI medical device

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
1,000

participants targeted

Target at P75+ for not_applicable diabetes-mellitus

Timeline
Completed

Started Jun 2024

Shorter than P25 for not_applicable diabetes-mellitus

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

June 7, 2024

Completed
3 days until next milestone

First Submitted

Initial submission to the registry

June 10, 2024

Completed
11 days until next milestone

First Posted

Study publicly available on registry

June 21, 2024

Completed
4 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 28, 2024

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 15, 2024

Completed
Last Updated

June 21, 2024

Status Verified

June 1, 2024

Enrollment Period

5 months

First QC Date

June 10, 2024

Last Update Submit

June 20, 2024

Conditions

Outcome Measures

Primary Outcomes (1)

  • Sensitivity and specificity

    The sensitivity and specificity will be calculated using the evaluation of independent masked expert (ophthalmologist) as gold standard.

    3 months

Study Arms (1)

one arm - 1000 patients, DR screening

EXPERIMENTAL

SW as medical devices(investigational device) to evaluate the retinal image of the patient's eye (to identify if the patient has DR or if the patient is healthy) .

Device: SW as medical devices(comperator) to evaluate the retinal image of the patient's eye (to identify if the patient has DR or if the patient is healthy) .

Interventions

second AI medical device to evaluate the retinal image of the patient's eye. two AI as MD will be evaluating the retinal image

one arm - 1000 patients, DR screening

Eligibility Criteria

Age40 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Men and women aged ≥ 40 years
  • Signed informed consent
  • Confirmed type 1 or 2 diabetes mellitus

You may not qualify if:

  • Ocular findings that do not allow retinal photography (significant nystagmus, corneal leukoma, dense cataract, hemophthalmus, etc.)
  • Patient has a condition or is in a situation that, in the opinion of the investigator, may bias the results of the study, may significantly interfere with the patient's participation in the investigation, or may result in unproducible photographs of a dilated ocular fundus
  • Patients with restrictions on personal freedom by administrative or legal order

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Jakub Sedivy

Příbram, Or, Czechia

RECRUITING

MeSH Terms

Conditions

Diabetes Mellitus

Condition Hierarchy (Ancestors)

Glucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesEndocrine System Diseases

Study Officials

  • Petr Šonka, MD

    GP

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Pavlina Kasparova Walter, MBA

CONTACT

Jiří Tomšej, ING

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
SCREENING
Intervention Model
SINGLE GROUP
Model Details: specific screening exhamination
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

June 10, 2024

First Posted

June 21, 2024

Study Start

June 7, 2024

Primary Completion

October 28, 2024

Study Completion

December 15, 2024

Last Updated

June 21, 2024

Record last verified: 2024-06

Data Sharing

IPD Sharing
Will not share

Locations